These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1785418)

  • 1. [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly].
    Uchibayashi T; Nakajima K; Nihino A; Hisazumi H
    Hinyokika Kiyo; 1991 Sep; 37(9):1077-85. PubMed ID: 1785418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence].
    Yamauchi K; Ohashi K; Osanai H; Inagaki N; Yamaguchi S; Hashimoto H; Yachiku S
    Hinyokika Kiyo; 1990 Dec; 36(12):1485-90. PubMed ID: 2075888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience in the use of propiverine hydrochloride (P-4) for patients suffering from urinary frequency and/or incontinence].
    Yokoyama O; Miyazaki K; Ishida T; Fujita Y; Hisazumi H
    Hinyokika Kiyo; 1990 Apr; 36(4):517-23. PubMed ID: 2378310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial].
    Goto M; Kato K; Kondo A; Otani T; Takita T; Kobayashi M
    Hinyokika Kiyo; 1988 Mar; 34(3):541-50. PubMed ID: 3389295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effectiveness of KL 007 (oxybutynin hydrochloride) in urinary disorders].
    Takimoto Y; Kiyotaki S; Kawazoe K; Fuse T; Kitamura K; Yamamoto T; Satoh Y; Okada K; Kishimoto T
    Hinyokika Kiyo; 1985 Dec; 31(12):2284-301. PubMed ID: 3832931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical effect of oxybutynin hydrochloride (1 mg/tablet)].
    Yokoyama E; Fujino A; Kubo S; Mashimo S; Koshiba K
    Hinyokika Kiyo; 1990 Jul; 36(7):869-76. PubMed ID: 2239587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
    López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
    Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children].
    Aubert D; Cencig P; Royer M
    Ann Pediatr (Paris); 1986 Sep; 33(7):629-34. PubMed ID: 3777773
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
    Mizunaga M; Miyata M; Kaneko S; Yachiku S; Chiba K
    Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of long-term administration of terodiline hydrochloride for the treatment of patients with pollakisuria and incontinence].
    Tsujimoto Y; Fujisue H; Shima H; Ikoma F; Sakurai T; Sato Y; Tokizane M; Akiyama K; Kato S; Nakachi K
    Hinyokika Kiyo; 1988 Apr; 34(4):724-32. PubMed ID: 3400552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effects of oxybutynin hydrochloride on neurogenic bladder].
    Toma H; Nakamura R
    Hinyokika Kiyo; 1986 Jun; 32(6):907-11. PubMed ID: 3532726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term therapy with Robaveron tablet (KN-7) for urinary disturbance].
    Tei K; Doi T; Sakai S; Fujimoto Y; Ban Y
    Hinyokika Kiyo; 1985 Apr; 31(4):731-8. PubMed ID: 2412422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of terodiline hydrochloride in patients with urinary frequency or incontinence].
    Yasuno H; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Kataoka N; Matsushita M; Inaba Y; Umezu K; Yamashita M
    Hinyokika Kiyo; 1991 Apr; 37(4):431-9. PubMed ID: 1892003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Propiverine hydrochloride improved correlatively subjective QOL and objective findings in Japanese patients with urinary frequency and/or incontinence].
    Noguchi K; Yamagishi T; Suzuki K; Kondo K; Kishida T; Saito K; Sekiguchi Y; Nakaigawa N; Ogawa T; Uemura H; Yao M; Kubota Y; Kawai M; Okajima K; Kobayashi K; Moriyama M; Kinoshita Y; Mikata K; Kitami K; Masuda M; Saito R; Murai T; Tomoda T; Noguchi S; Sakai N; Hamano A; Nomura S; Sato K
    Hinyokika Kiyo; 2006 May; 52(5):343-8. PubMed ID: 16758722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of terodiline hydrochloride for the treatment of urinary frequency and urinary incontinence, and its cardiovascular adverse effects].
    Yoshihara H; Yasumoto R; Kishimoto T; Maekawa M; Horii A; Nishijima T; Sugimoto T; Kashiwara N; Tsujita M; Senjyu M
    Hinyokika Kiyo; 1992 Aug; 38(8):967-72. PubMed ID: 1414748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.